Real-World DATA Analysis of Antiretroviral Treatment for HIV-Infected Adult Patients in Ukraine

Author(s)

Vysotska O1, Piniazhko O2, Vysotskyi V1, Masheiko A3, Serediuk V4, Leleka M4
1The Educational and Research Center – Ukrainian Family Medicine Training Center of Bogomolets National Medical University, Kyiv, Ukraine, 2State Expert Center (SEC) of Ministry of Health, Kyiv, Ukraine, 3State Expert Center of the Ministry of Health of Ukraine, Kyiv, BC, Ukraine, 4State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine

OBJECTIVES. Real-world data analysis is an integral part in determining the expediency of financial expenses for medical prescriptions. For this purpose, real-world data analysis of treatment for HIV-infected adult patients in Ukraine was conducted.

METHODS. ABC/VEN-analysis has been recommended by the WHO for analysis of the feasibility of using medical resources in real clinical practice. The subject of this analysis was the medical documentation of 326 adult patients with HIV/AIDS from five Regional Centers for HIV/AIDS Prevention and Control for the period 2017–2019. The direct medical costs were calculated based on drug manufacturers' prices from the MoH registry dated by 20 August 2020.

RESULTS. It was found that for 326 patients with the average age of 42 years were prescribed 19 antiretroviral treatment schemes. The average cost of the annual course was USD 380.96 per one patient and USD 125,642.68 for all prescriptions. All analyzed medicines were included either in the clinical guideline of antiretroviral treatment, or the 21st WHO Model List of Essential Medicines or the National List of Essential Medicines of Ukraine. That proves the clinical effectiveness of prescribed medicines and expediency of financial resources for the medical provision of HIV/AIDS patients. ABC-analysis showed that category A consisted of 5 schemes, B - 4 schemes and category C - 10 schemes. In the cost structure of the antiretroviral treatment tenofovir disoproxil fumarate/emtricitabine/efavirenz (TDF/FTC/EFV), tenofovir disoproxil fumarate/emtricitabine combined with dolutegravir (TDF/FTC+DTG), tenofovir/ emtricitabine combined with lopinavir/ritonavir (TDF/FTC+LPV/r), abacavir/lamivudine combined with lopinavir/ritonavir (ABC/ЗTС+LPV/r) and zidovudine/lamivudine combined with lopinavir/ritonavir (AZT/3TC+LPV/r) had the highest shares (20.3%, 19.3%, 15.1%, 12.2% and 9.5% respectively).

CONCLUSIONS. ABC/VEN analysis of the real-world data showed that medicines for the antiretroviral treatment for adult HIV-infected patients in Ukraine correspond to the international treatment guidelines and regulatory lists which provides reliable additional evidence for the health technology assessment.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Code

PIN79

Topic

Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Real World Data & Information Systems

Topic Subcategory

Distributed Data & Research Networks, Hospital and Clinical Practices, Public Spending & National Health Expenditures

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×